Streetbeat News

Analyst Ratings

SO

Barclays analyst Eric Beaumont has maintained an Equal-Weight rating on Southern Company (NYSE:SO) but reduced the price target from $68 to $67. This adjustment reflects a slightly more cautious stance on the stock's valuation.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 11:39 am

XEL

Barclays analyst Eric Beaumont has maintained an Equal-Weight rating on Xcel Energy (NASDAQ:XEL) and increased the price target from $61 to $62.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 11:32 am

DTM

Barclays analyst Marc Solecitto has maintained an Overweight rating on DT Midstream (NYSE:DTM) and increased the price target from $57 to $59, indicating a positive outlook on the stock.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 11:31 am

CMS

Barclays analyst Eric Beaumont has maintained an Equal-Weight rating on CMS Energy (NYSE:CMS) and increased the price target from $55 to $59.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 11:26 am

ELTX

HC Wainwright & Co. analyst Robert Burns has maintained a Buy rating on Elicio Therapeutics (NASDAQ:ELTX) and increased the price target from $10 to $11. This adjustment reflects a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 11:25 am

APLS

HC Wainwright & Co. analyst Douglas Tsao has reaffirmed a Buy rating on Apellis Pharmaceuticals (NASDAQ:APLS) and increased the price target from $82 to $92, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 11:23 am

EOLS

HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Evolus (NASDAQ:EOLS) and maintained a $27 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 11:21 am

LNG

Barclays analyst Marc Solecitto has maintained an Overweight rating on Cheniere Energy (AMEX:LNG) and increased the price target from $192 to $194.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 11:21 am

AEE

Barclays analyst Eric Beaumont has maintained an Equal-Weight rating on Ameren (NYSE:AEE) and increased the price target from $71 to $72, indicating a neutral outlook with a slight positive adjustment on the company's stock value.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 11:18 am

RXRX

Needham analyst Gil Blum has reiterated a Buy rating on Recursion Pharmaceuticals (NASDAQ:RXRX) and maintained a $15 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 11:18 am